Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
|Videos|July 25, 2021
Disruptive companies continue to affect ODs
Advertisement
Disruptive companies are looking to make money by coming between the doctor and the patient, especially in the contact lens market. Jeff Sonsino, OD, FAAO, suggests private practice ODs have tools at their disposal to help them compete.
Advertisement
Related to this article
This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.
The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.
Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.
Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: October 26-30
2
From our Editorial Board: Comments from the FDA Advisory Committee meeting on SYD-101
3
Contact lens case hygiene among most skipped steps in lens care
4
First genotype-guided dry eye trial, PREDICT-1, completes randomization
5